11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      CXCL10 Is a Circulating Inflammatory Marker in Patients with Advanced Heart Failure: a Pilot Study.

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Chemokines are involved in the remodeling of the heart; however, their significance as biomarkers in heart failure is unknown. We observed that circulating CXCR3 receptor chemokines CXCL9 and CXCL10 in a rat model of heart failure were increased 1 week after myocardial infarction. CXCL10 was also increased in both remote and infarcted regions of the heart and remained elevated at 16 weeks; CXCL9 was elevated in the remote area at 1 week. In humans, hierarchical clustering and principal component analysis revealed that circulating CXCL10, MIP-1α, and CD40 ligand were the best indicators for differentiating healthy and heart failure subjects. Serum CXCL10 levels were increased in patients with symptomatic heart failure as indexed by NYHA classification II through IV. The presence of CXCL10, MIP-1α, and CD40 ligand appears to be dominant in patients with advanced heart failure. These findings identify a distinct profile of inflammatory mediators in heart failure patients.

          Related collections

          Author and article information

          Journal
          J Cardiovasc Transl Res
          Journal of cardiovascular translational research
          Springer Nature
          1937-5395
          1937-5387
          Aug 2016
          : 9
          : 4
          Affiliations
          [1 ] Department of Pharmacology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands. raltara@umc.edu.
          [2 ] Department of Pharmacology and Toxicology, School of Medicine, University of Mississippi Medical Center, 2500 North State St., Jackson, MS, 39216-4505, USA. raltara@umc.edu.
          [3 ] DG-DI, Medical Applications, CERN, Geneva, Switzerland.
          [4 ] Leiden University Medical Center, Leiden, The Netherlands.
          [5 ] Studies Coordinating Centre, Research Unit Hypertension, Leuven, Belgium.
          [6 ] Cardiovascular Epidemiology, KU Leuven Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium.
          [7 ] Department of Cardiology, Thoraxcenter, Erasmus MC, Rotterdam, The Netherlands.
          [8 ] Department of Pharmacology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, The Netherlands.
          [9 ] Department of Pharmacology and Toxicology, School of Medicine, University of Mississippi Medical Center, 2500 North State St., Jackson, MS, 39216-4505, USA.
          Article
          10.1007/s12265-016-9703-3
          10.1007/s12265-016-9703-3
          27271043
          3a0a88c0-2f63-45f3-ad45-576c7cbb05b3
          History

          CXCR3,Chemokines,Immune response,Inflammation
          CXCR3, Chemokines, Immune response, Inflammation

          Comments

          Comment on this article

          scite_
          80
          2
          56
          1
          Smart Citations
          80
          2
          56
          1
          Citing PublicationsSupportingMentioningContrasting
          View Citations

          See how this article has been cited at scite.ai

          scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.

          Similar content653

          Cited by46